The estimated Net Worth of Jeffery S Thompson is at least $1.87 Milion dollars as of 11 March 2022. Mr. Thompson owns over 2,000 units of Anika Therapeutics stock worth over $415,184 and over the last 14 years he sold ANIK stock worth over $1,256,716. In addition, he makes $201,369 as Independent Director at Anika Therapeutics.
Jeffery has made over 4 trades of the Anika Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of ANIK stock worth $49,320 on 11 March 2022.
The largest trade he's ever made was selling 10,725 units of Anika Therapeutics stock on 19 May 2017 worth over $508,258. On average, Jeffery trades about 1,396 units every 144 days since 2011. As of 11 March 2022 he still owns at least 17,121 units of Anika Therapeutics stock.
You can see the complete history of Mr. Thompson stock trades at the bottom of the page.
Jeffery S. Thompson serves as Independent Director of the Company. He is a Partner with HealthEdge Investment Partners, LLC (“HealthEdge”), a Tampa, Florida based private equity firm that provides strategic capital exclusively in the healthcare industry. Mr. Thompson currently serves as a director for various HealthEdge affiliated companies including AMC, Formulated Solutions, Santus, MNG Laboratories, Columbus Group, and Data Dimensions, LLC. Mr. Thompson also serves as a non-executive director for Sinclair Pharma, plc, a publicly traded, London-based, international aesthetic dermatology company. Prior to joining Anika, he served as President, Chief Executive Officer and Chairman of Advanced Bio-Technologies and Enaltus, HealthEdge portfolio companies specializing in skincare solutions. Mr. Thompson also served as a director and the Chief Operating Officer for Stiefel Laboratories, Inc. (“Stiefel”), an independent pharmaceutical company specializing in dermatology. Prior to his Chief Operating Officer role, he was Stiefel’s Senior Vice President of U.S. Business Services and President of Glades Pharmaceuticals. Earlier in his career, Mr. Thompson held sales and business management positions at Bausch & Lomb Pharmaceuticals and SmithKline Beecham. Mr. Thompson holds a B.S. in general science from the University of Pittsburgh.
As the Independent Director of Anika Therapeutics, the total compensation of Jeffery Thompson at Anika Therapeutics is $201,369. There are 8 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
Jeffery Thompson is 54, he's been the Independent Director of Anika Therapeutics since 2011. There are 13 older and 4 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia oraz Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
Anika Therapeutics executives and other stock owners filed with the SEC include: